AB Restore — P/V Shot MAX Exosomes

Overview

Parent Cell: Equal blend of Akira MSC Exosomes, Akira Neural Exosomes, and Akira Muscle Exosomes | Next-generation intimate wellness exosome therapy in a tri-lineage formulation targeting erectile dysfunction, sexual wellness, and intimate tissue regeneration

Related: Exosomes Overview

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

What Are Exosomes?

Exosomes are nanoscale extracellular vesicles (40–150 nm) formed by inward budding of endosomal multivesicular bodies (MVBs) and released upon MVB fusion with the plasma membrane. They carry a protected cargo of mRNAs, miRNAs, proteins, lipids, and signaling molecules from their parent cell, delivering this molecular payload to recipient cells with high specificity and efficiency. Unlike the parent cell, exosomes carry no nuclear material and cannot self-replicate — providing a cell-free therapeutic profile with superior safety and stability characteristics.

Mechanism of Action & Molecular Cargo

Erectile dysfunction, female sexual dysfunction, and related pelvic/genital tissue disorders share a broadly analogous, multifactorial pathophysiology spanning vascular insufficiency, peripheral nerve loss, and smooth muscle/connective tissue degeneration.^[1][2] Rather than relying on a single mechanism the way platelet-rich plasma protocols (the P-Shot and O-Shot) and single-lineage exosome products do, this blend combines MSC-lineage, neural-lineage, and skeletal-muscle-lineage exosomes into one cell-free injectable targeting the vascular, neural, and structural axes of intimate tissue dysfunction simultaneously.^[3]

Vascular Regeneration (MSC Exosome Component): VEGF, eNOS mRNA, and miR-126 activate endothelial NO production and angiogenesis in penile/vaginal microvasculature.^[4] NO-mediated smooth muscle relaxation enables engorgement, directly addressing vascular ED.

Neural Sensitivity Restoration (Neural Exosome Component): BDNF, GDNF, and miR-132 support peripheral nerve regeneration and sensitivity in genital tissue.^[5] Nerve fiber density improvement directly translates to enhanced sensation and arousal response.

Smooth Muscle & Tissue Firmness (Muscle Exosome Component): miR-206, IGF-1, and myogenic cargo restore corpus cavernosal smooth muscle tone, contractility, and structural integrity — key determinants of erectile rigidity and vaginal tissue turgor.

Collagen Remodeling: TGF-β modulation from MSC exosome fraction drives type I collagen synthesis in connective tissue, improving structural support and reducing Peyronie's plaque — relevant for penile tissue remodeling applications.^[6]

Anti-Fibrotic & Anti-Inflammatory: Combined anti-fibrotic miRNA cargo from all three fractions prevents profibrotic degeneration of intimate tissue — addressing Peyronie's disease, vaginal fibrosis post-radiation, and postpartum connective tissue changes.

Key Molecular Cargo

Potential Applications

• Men: Erectile Dysfunction (vascular, neurogenic, mixed) — primary indication
• Men: Peyronie's Disease — anti-fibrotic plaque modulation^[6]
• Men: Girth Enhancement (combined with vacuum therapy protocols)
• Men: Post-prostatectomy ED — neural and vascular recovery
• Women: Sexual Dysfunction / Reduced Arousal
• Women: Vaginal Dryness / Atrophic Vaginitis (non-hormonal treatment)
• Women: Postpartum Pelvic Floor Recovery
• Women: Urinary Stress Incontinence — urethral sphincter and pelvic floor support
• Both: Post-cancer treatment sexual dysfunction (radiation, hormone therapy)

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Clinical & Preclinical Evidence

The vascular mechanism of P-Shot enhancement is supported by eNOS/NO pathway data from endothelial cell studies showing 75% improvement in blood flow in ischemic tissue models using endothelial-specific exosome preparations — directly applicable to penile microvascular insufficiency.^[7]

MSC-derived exosomes ameliorate erectile dysfunction by alleviating corpus cavernosum smooth muscle apoptosis in a rat model of cavernous nerve injury, supporting the vascular/smooth-muscle rationale for this blend.^[8]

Neural exosome BDNF/GDNF delivery data demonstrates peripheral nerve density restoration in diabetic neuropathy models — relevant to diabetic ED where peripheral autonomic denervation contributes to vascular dysfunction, an area now under direct clinical investigation combining MSC and exosome therapy for diabetic erectile dysfunction.^[9]

Muscle exosome miR-206/IGF-1 data from sarcopenia models confirms smooth muscle fiber maintenance and contractility support — addressing the corpus cavernosal smooth muscle loss that characterizes advanced ED.

Pilot and systematic-review data on platelet-rich plasma (P-Shot) intracavernosal injection establish both the procedural precedent and the efficacy ceiling this tri-lineage exosome blend is designed to exceed.^[10][11]

The triple-blend rationale is supported by the multifactorial pathophysiology of ED and female sexual dysfunction, where vascular, neural, and structural components all contribute. Single-modality treatments (PDE5 inhibitors alone, O-shot/PRP alone) address only one pathway; the AB Restore product targets all three simultaneously.

Clinical practitioners using combined exosome protocols for intimate wellness report significantly improved patient satisfaction scores, faster response onset (vs PRP alone), and 6–12 month duration of effect — consistent with the multi-pathway regenerative mechanism. A pilot phase non-randomized controlled trial of intracavernous stem-cell-derived bioactive molecule injection for erectile dysfunction supports this treatment class, and a broader stem cell/exosome erectile dysfunction trial (RISE) is now underway.^[12][3]

Women using platelet-derived exosome injections for sexual dysfunction have shown improvement in a retrospective clinical review, supporting the cross-sex rationale for the exosome-based approach used here.^[13]